A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (Dahanca) protocol 5–85: Overgaard J, Hansen HS, Overgaard M, Basthold L, Berthelsen A, Specht L, Lindelov B, Jorgensen K Radioth Oncol 1998; 46 : 135–146